80 Results for "

lag-3

" in MedChemExpress (MCE) Product Catalog:
Products (80)

80 Results for "lag-3" in MCE Product Catalog:

  • Targets Recommended:
3
3 Cited Publications
Cat. No.: HY-P99156
CAS No.: 1673516-98-7
Synonyms: BMS-986016

Target:  

LAG-3

Research Areas:  

Cancer

Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108691
CAS No.: 1407966-77-1
Purity:  99.48%
Target:  

Itk Btk CXCR PD-1/PD-L1 LAG-3

Research Areas:  

Cancer

PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-144088
CAS No.: 2380300-79-6
Purity:  98.86%
Synonyms: HPK1-IN-22
Target:  

MAP4K

Research Areas:  

Inflammation/Immunology Cancer

ZYF0033 is an orally active inhibitor of the hematopoietic progenitor cell kinase HPK1 with an IC50 of less than 10 nM based on the phosphorylation inhibition of MBP protein. ZYF0033 promotes anti-cancer immune responses and reduces phosphorylation of SLP76 (serine 376). ZYF0033 inhibits tumor growth in the 4T-1 syngeneic mouse model and leads to increased intratumoral infiltration of DCs, NK cells, and CD107a +CD8 + T cells, but not T cells, PD-1 +CD8 + T cells, TIM-3 +CD8 + Infiltration of T cells and LAG3 +CD8 + T cells was reduced .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99736
CAS No.: 2249882-55-9
Synonyms: BI-754111

Target:  

LAG-3

Research Areas:  

Cancer

Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P70723
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Lymphocyte activation gene 3 protein; lag3; lag-3; Protein FDC; CD223
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P99617
CAS No.: 2126132-98-5
Synonyms: REGN3767

Target:  

LAG-3

Research Areas:  

Inflammation/Immunology Cancer

Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity .
loading...
    loading...
Cat. No.: HY-P99613
CAS No.: 2231068-83-8
Synonyms: MK-4280; Mavezelimab

Target:  

LAG-3

Research Areas:  

Cancer

Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma . For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
loading...
    loading...
Cat. No.: HY-P99141

Target:  

LAG-3

Research Areas:  

Inflammation/Immunology Cancer

Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 + T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) [3].
loading...
    loading...
Cat. No.: HY-176813
Target:  

LAG-3

Research Areas:  

Cancer

LAG-3 Hit II is a LAG-3 inhibitor with a KD of 4.32  μM. LAG-3 Hit II can be used for cancers like ovarian cancer, colon adenocarcinoma and melanoma research .
loading...
    loading...
Cat. No.: HY-P99573
CAS No.: 2245725-04-4
Synonyms: MGD-013

Target:  

LAG-3

Research Areas:  

Inflammation/Immunology Cancer

Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity [3].
loading...
    loading...
Cat. No.: HY-P99922
CAS No.: 2173096-82-5

Target:  

LAG-3

Research Areas:  

Cancer

Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .
loading...
    loading...
Cat. No.: HY-162811
CAS No.: 1830484-40-6
Target:  

LAG-3

Research Areas:  

Cancer

LAG-3 biner 1 (compound 3) is a small molecule ligand (Kd=1.23 μM) for the immune checkpoint lymphocyte activation gene 3 (LAG-3). LAG-3 biner 1 can be used in the research of cancer diagnosis targeting LAG-3 .
loading...
    loading...
Cat. No.: HY-P991301

Target:  

LAG-3

Research Areas:  

Cancer

IMP-761 is a human IgG4 monoclonal antibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
loading...
    loading...
Cat. No.: HY-172930
CAS No.: 2991021-08-8
PVTX-405 is a selective and oral active IKZF2 molecular glue degrader with a DC50  of  0.7 nM and a Dmax of 91%. PVTX-405 enhances degradation efficiency, significantly reduces off-target degradation, and alleviates hERG inhibition with IC50 of 48 µM. PVTX-405 significantly inhibits the growth of MC38 tumors, with greater synergistic anti-cancer efficacy in combination with immune checkpoint therapies (ICTs) (anti-PD1 or anti-LAG3) in the MC38 mouse tumor xenograft model using Crbn 391V C57BL/6 mice .
loading...
    loading...
Cat. No.: HY-179060
Target:  

PROTACs LAG-3

Research Areas:  

Cancer

LAG-3 PROTAC-1 is a potent LAG-3 PROTAC degrader with a DC50 of 0.27 μM. LAG-3 PROTAC-1 can be used in cancer immunology research .
loading...
    loading...
Cat. No.: HY-P99027
CAS No.: 2137049-37-5
Synonyms: lag525; IMP701; Hu5A8

Target:  

LAG-3

Research Areas:  

Cancer

Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
loading...
    loading...
Cat. No.: HY-P10835
Target:  

LAG-3

Research Areas:  

Cancer

LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a Kd value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8 + T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .
loading...
    loading...
Cat. No.: HY-P10837
Target:  

LAG-3

Research Areas:  

Inflammation/Immunology Cancer

LAG-3 cyclic peptide inhibitor 12 (Cyclic peptide 12) is an inhibitor of LAG-3 with an IC50 value of 4.45 μM and a Ki value of 2.66 µM .
loading...
    loading...
Cat. No.: HY-149916
CAS No.: 2922920-71-4
Target:  

Adenosine Receptor

Research Areas:  

Cancer

A2AR-antagonist-1 (compound 38) is an orally active adenosine A2A receptor (A2AR) antagonist (IC50=29 nM). A2AR-antagonist-1 exhibits anti-tumor activity and mouse liver microsomal metabolic stability (t1/2=86.1 min). A2AR-antagonist-1 is also a T cells activator, via inhibiting immunosuppressive molecules (LAG-3 and TIM-3) and enhancing effector molecules (GZMB, IFNG, and IL-2) .
loading...
    loading...
Cat. No.: HY-176814
Target:  

LAG-3

Research Areas:  

Cancer

LAG-3-IN-1 (Compound 11) is a LAG-3 inhibitor with a KD of 0.41  μM. LAG-3-IN-1 disrupts the LAG-3/MHCII interaction, enhances IFN-γ secretion and promotes tumor cell killing in cocultures of PBMCs and cancer cells. LAG-3-IN-1 can be used for cancers like ovarian cancer, colon adenocarcinoma and melanoma research .
loading...
    loading...